Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 21 DAY versus ENSKYCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 21 DAY versus ENSKYCE.
BREVICON 21-DAY vs ENSKYCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-17 hours. Clinical context: Steady state reached within 5-7 days; missed pills may reduce contraceptive efficacy.
12 hours (terminal); allows once-daily dosing in most patients
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); biliary (minor).
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive